ASS1 and melanoma: The results showed that patients with negative ASS1 expression had a higher clinical benefit rate and a longer time to progression compared to patients with positive ASS1 expression, suggesting that ADI-PEG 20 is only effective in melanoma patients whose tumors have negative ASS1 expression.